sb 203580 has been researched along with Proteinuria in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cheng, H; Jiang, D; Jin, N; Wang, Q; Zhang, X; Zhu, K | 1 |
1 other study(ies) available for sb 203580 and Proteinuria
Article | Year |
---|---|
The selective p38 mitogen-activated protein kinase inhibitor, SB203580, improves renal disease in MRL/lpr mouse model of systemic lupus.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Complement C3; Creatinine; Female; Hepatocytes; Imidazoles; Immunoglobulins; Kidney; Kidney Diseases; Liver; Lupus Erythematosus, Systemic; Mice; Mice, Inbred C57BL; p38 Mitogen-Activated Protein Kinases; Proteinuria; Pyridines; Spleen | 2011 |